



09/536728

8/19/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Franz Esser *et al.*

Examiner: Fiona T. Powers

Serial No.: 09/536,728

Group Art Unit: 1626

Filed: March 28, 2000

Docket: 1/1003-2-D1

For: USE OF α_1 L AGONISTS FOR TREATING URINARY INCONTINENCEAssistant Commissioner for Patents
Washington DC 20231

RECEIVED

JUL 25 2002

TECH CENTER 1600/2900

AMENDMENT UNDER 37 C.F.R. § 1.111
IN RESPONSE TO MAY 9, 2002, OFFICE ACTION

Sir:

This Amendment is filed in response to the Office Action of May 9, 2002. In that Office Action, a three month shortened statutory period was set for response, and this Amendment is therefore timely. If it is determined that any fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Amendment, authorization is hereby given to charge such fees to Deposit Account No. 02-2955.


18/1
Rham
8/19/02

In the Claims:

In accordance with 37 C.F.R. § 1.121(c), please amend claims 21, 29, 34, 35, 38, 39, and 51 to 54 by rewriting them in clean form as follows (the marked up version of the amended claims follows the Remarks).

08/20/2002 RHARHMAN 00000001-022955 09536728

01 FC:102

84.00 CH
--21. (Four times amended) A compound of the formula (II)

wherein:

R¹ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C₃₋₆-cycloalkyl, C₁₋₆-alkoxy, halogen, -CF₃, or -OCF₃;

R² is -NR⁶R⁷, wherein

07/24/2002 NMOHAMM1 00000062 022955 09536728

01 FC:103 18.00 CH
02 FC:102 588.00 CH